Pasar al contenido principal

PROCESAMIENTO ANOMALO DEL MARN EN LA CONVERGENCIA DE LA ENFERMEDAD DE HUNTINGTON Y OTRAS PATOLOGIAS NEURALES

PID2021-123141OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CPEB4–CLOCK crosstalk during temporal lobe epilepsy

  • de Diego-Garcia, Laura
  • Brennan, Gary P
  • Auer, Theresa
  • Menendez-Mendez, Aida
  • Parras, Alberto
  • Martin-Gil, Alba
  • Mitra, Meghma
  • Ollà, Ivana
  • Villalba-Benito, Leticia
  • Gil, Beatriz
  • Alves, Mariana
  • Lau, Kelvin
  • Delanty, Norman
  • Beausang, Alan
  • Cryan, Jane
  • Brett, Francesca M.
  • Farrell, Michael A.
  • O'Brien, Donncha F.
  • Mendez, Raúl
  • Carracedo-Rodríguez, Gonzalo
  • Henshall, David C
  • Lucas, José J
  • Engel, Tobias
Objective: Posttranscriptional mechanisms are increasingly recognized as important contributors to the formation of hyperexcitable networks in epilepsy. Messenger RNA (mRNA) polyadenylation is a key regulatory mechanism governing protein expression by enhancing mRNA stability and translation. Previous studies have shown large-scale changes in mRNA polyadenylation in the hippocampus of mice during epilepsy development. The cytoplasmic polyadenylation element-binding protein CPEB4 was found to drive epilepsy-induced poly(A) tail changes, and mice lacking CPEB4 develop a more severe seizure and epilepsy phenotype. The mechanisms controlling CPEB4 function and the downstream pathways that influence the recurrence of spontaneous seizures in epilepsy remain poorly understood. Methods: Status epilepticus was induced in wild-type and CPEB4-deficient male mice via an intra-amygdala microinjection of kainic acid. CLOCK binding to the CPEB4 promoter was analyzed via chromatin immunoprecipitation assay and melatonin levels via high-performance liquid chromatography in plasma. Results: Here, we show increased binding of CLOCK to recognition sites in the CPEB4 promoter region during status epilepticus in mice and increased Cpeb4 mRNA levels in N2A cells overexpressing CLOCK. Bioinformatic analysis of CPEB4-dependent genes undergoing changes in their poly(A) tail during epilepsy found that genes involved in the regulation of circadian rhythms are particularly enriched. Clock transcripts displayed a longer poly(A) tail length in the hippocampus of mice post-status epilepticus and during epilepsy. Moreover, CLOCK expression was increased in the hippocampus in mice post-status epilepticus and during epilepsy, and in resected hippocampus and cortex of patients with drug-resistant temporal lobe epilepsy. Furthermore, CPEB4 is required for CLOCK expression after status epilepticus, with lower levels in CPEB4-deficient compared to wild-type mice. Last, CPEB4-deficient mice showed altered circadian function, including altered melatonin blood levels and altered clustering of spontaneous seizures during the day. Significance: Our results reveal a new positive transcriptional–translational feedback loop involving CPEB4 and CLOCK, which may contribute to the regulation of the sleep–wake cycle during epilepsy., H2020 Marie Skłodowska-Curie Actions, Grant/Award Number:766124 and 796600; Irish Research Council, Grant/Award Number:GOIPD/2020/806; Programa de Atracción de Talento de la Comunidad de Madrid, Grant/Award Number: 2020-T2/BMD- 20180; Science Foundation Ireland, Grant/Award Number:16/RC/3948 and 17/CDA/4708;Spanish Ministry of Economy and Competitiveness/Ministry of Science, Innovation and Universities, Grant/Award Number: PID2021- 123141OB- I00, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pathogenic Mis-splicing of CPEB4 in Schizophrenia

  • Ollà, Ivana
  • Pardiñas, Antonio F.
  • Parras, Alberto
  • Hernández, Ivó H.
  • Santos-Galindo, María
  • Picó, Sara
  • Callado, Luis F.
  • Elorza, Ainara
  • Rodríguez-López, Claudia
  • Fernández-Miranda, Gonzalo
  • Belloc, Eulàlia
  • Walters, James T. R.
  • O'Donovan, Michael C.
  • Méndez, Raúl
  • Toma, Claudio
  • Meana, J. Javier
  • Owen, Michael J.
  • Lucas, José J.
Background: Schizophrenia (SCZ) is caused by an interplay of polygenic risk and environmental factors, which may alter regulators of gene expression leading to pathogenic misexpression of SCZ risk genes. The CPEB family of RNA-binding proteins (CPEB1–4) regulates translation of target RNAs (approximately 40% of overall genes). We previously identified CPEB4 as a key dysregulated translational regulator in autism spectrum disorder (ASD) because its neuronal-specific microexon (exon 4) is mis-spliced in ASD brains, causing underexpression of numerous ASD risk genes. The genetic factors and pathogenic mechanisms shared between SCZ and ASD led us to hypothesize CPEB4 mis-splicing in SCZ leading to underexpression of multiple SCZ-related genes. Methods: We performed MAGMA-enrichment analysis on Psychiatric Genomics Consortium genome-wide association study data and analyzed RNA sequencing data from the PsychENCODE Consortium. Reverse transcriptase polymerase chain reaction and Western blot were performed on postmortem brain tissue, and the presence/absence of antipsychotics was assessed through toxicological analysis. Finally, mice with mild overexpression of exon 4–lacking CPEB4 (CPEB4Δ4) were generated and analyzed biochemically and behaviorally. Results: First, we found enrichment of SCZ-associated genes for CPEB4-binder transcripts. We also found decreased usage of CPEB4 microexon in SCZ probands, which was correlated with decreased protein levels of CPEB4-target SCZ-associated genes only in antipsychotic-free individuals. Interestingly, differentially expressed genes fit those reported for SCZ, specifically in the SCZ probands with decreased CPEB4-microexon inclusion. Finally, we demonstrated that mice with mild overexpression of CPEB4Δ4 showed decreased protein levels of CPEB4-target SCZ genes and SCZ-linked behaviors. Conclusions: We identified aberrant CPEB4 splicing and downstream misexpression of SCZ risk genes as a novel etiological mechanism in SCZ., his work was supported by grants to JJL from: Networking Research Center on Neurodegenerative Diseases (CIBERNED) - Health Institute Carlos III (ISCIII) (Collaborative Grant No. PI2018/06-1), Spanish Ministry of Economy and Competitiveness (MINECO) (Grant No. SAF2015-65371-R), Spanish Ministry of Science, Innovation and Universities (MICIU) (Grant No. RTI2018-096322-B-I00) and Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033/FEDER,UE Grant No. PID2021-123141OB-I00); by grants to RM from MINECO (PID2020-119533GB-I00) and World Cancer Research Fund International (2020_021); by grants to CT: No. PID2020-114996RB-I00 (MCIU/AEI/FEDER,UE) and RyC2018-024106-I; and by grants to JJM and LFC from Basque Government (Grant Nos. IT-1211-19 and 1512-22). Cardiff University’s work was supported by grants to JTRW, MCO, and MJO from Medical Research Council Centre (Grant No. MR/L010305/1), Program (Grant No. MR/P005748/1), and Project (Grant Nos. MR/L011794/1, MC_PC_17212). AFP was supported by an Academy of Medical Sciences “Springboard” award (SBF005∖1083). IO was hired through European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (Grant No. 766124). The Center for Molecular Biology Severo Ochoa is a Severo Ochoa Center of Excellence (MICIN, Award CEX2021-001154-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001154-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ

  • Li, Xuexin
  • Hernandez, Ivó
  • Koyuncu, Seda
  • Kis, Balázs
  • Häggblad, Maria
  • Lidemalm, Louise
  • Abbas, Anna A.
  • Bendegúz, Sramkó
  • Göblös, Anikó
  • Brautigam, Lars
  • Lucas, Jose J.
  • Carreras-Puigvert, Jordi
  • Hühn, Daniela
  • Pircs, Karolina
  • Vilchez, David
  • Fernandez-Capetillo, Oscar
Background: PolyQ diseases are autosomal dominant neurodegenerative disorders caused by the expansion of CAG repeats. While of slow progression, these diseases are ultimately fatal and lack effective therapies. Methods: A high-throughput chemical screen was conducted to identify drugs that lower the toxicity of a protein containing the first exon of Huntington's disease (HD) protein huntingtin (HTT) harbouring 94 glutamines (Htt-Q). Candidate drugs were tested in a wide range of in vitro and in vivo models of polyQ toxicity. Findings: The chemical screen identified the anti-leprosy drug clofazimine as a hit, which was subsequently validated in several in vitro models. Computational analyses of transcriptional signatures revealed that the effect of clofazimine was due to the stimulation of mitochondrial biogenesis by peroxisome proliferator-activated receptor gamma (PPARγ). In agreement with this, clofazimine rescued mitochondrial dysfunction triggered by Htt-Q expression. Importantly, clofazimine also limited polyQ toxicity in developing zebrafish and neuron-specific worm models of polyQ disease. Interpretation: Our results support the potential of repurposing the antimicrobial drug clofazimine for the treatment of polyQ diseases. Funding: A full list of funding sources can be found in the acknowledgments section., We thank the Chemical Biology Consortium Sweden for their help with the chemical libraries. Research was funded by grants from the Cancerfonden foundation (CAN 21/1529) and the Swedish Research Council (VR) (538-2014-31) to OF; and the Spanish Ministry of Science and Innovation and Spanish Ministry of Science (PID2021-123141OBI00 MCIU/AEI/FEDER, UE) to JJL, and the ICGEB CRP/HUN21-05_EC and the TKP-NVA-20 to KP. None of the funders contributed to the design, analysis or reporting of this study.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Down-regulation of neuroprotective protein kinase D in Huntington¿s disease

  • Sebastián-Serrano, Álvaro
  • Simón-García, Ana
  • Santos-Galindo, María
  • Sánchez-Carralero, Marina Prudencio
  • Hernández Alcántara, Alberto
  • Clemente, Cristina
  • Pose-Utrilla, Julia
  • Campanero, Miguel R.
  • Porlan, Eva
  • Lucas, José J.
  • Iglesias, Teresa
Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder characterized by the selective dysfunction and loss of neurons in the striatum and cerebral cortex. Experimental evidence suggests that GABAergic medium-sized spiny neurons (MSNs) in the striatum are particularly vulnerable to glutamate-induced toxicity (excitotoxicity) and its analogues. However, the molecular mechanisms underlying MSN-specific death in HD remain poorly understood. The serine/threonine protein kinase D1 (PKD1) confers neuroprotection in various neuropathological conditions, including ischemic stroke. While excitotoxicity inactivates PKD1 in cortical glutamatergic neurons without altering its levels, active PKD1 potentiates the survival of excitatory neurons in highly excitotoxic environments. Here, we investigated whether PKD1 activity dysregulation contributes to MSN death in HD and its association with neurodegeneration. We found an unexpected reduction in PKD1 protein levels in striatal neurons from HD patients. Similarly, the R6/1 mouse model of HD exhibited progressive PKD1 protein loss, commencing at early disease stages, accompanied by decreased Prkd1 transcript levels. PKD1 downregulation also occurred in the cerebral cortex of R6/1 mice, but only at late stages. Functionally, pharmacological PKD inhibition in primary striatal neurons exacerbated excitotoxic damage and apoptosis induced by glutamate N-methyl D-aspartate (NMDA) receptors, whereas expression of constitutively active PKD1 (PKD1-Ca) conferred neuroprotection. Furthermore, PKD1-Ca protected against polyQ-induced apoptosis in a cellular model of HD. In a translational approach, intrastriatal lentiviral delivery of PKD1-Ca in symptomatic R6/1 mice prevented the loss of DARPP-32, a molecular marker of MSNs. Collectively, our findings strongly suggest that PKD1 loss-of-function contributes to HD pathogenesis and the selective vulnerability of MSNs. These findings position PKD1 as a promising therapeutic target for mitigating MSN death in HD., This work was funded by grants PID2020-115218RB-I00 to TI and PID2021-123141OB-I00 to JJL, funded by MCIN/AEI/ 10.13039/501100011033; PID2023-153284OB-100 to TI, PID2023-152367OB-I00 to MRC and PID2023-146945NB-I00 to EP, funded by MCIU/AEI/ 10.13039/501100011033 and by ERDF/EU; and collaborative grants CIBERNED-2018/06 and 2022/03 to TI and JJL funded by Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED, Instituto de Salud Carlos III, Spain). AS-S was funded by a contract from CIBERNED-2018-06 collaborative project and is recipient of a Ramon y Cajal contract, reference RYC2022-035922-I, funded by MCIN/AEI/10.13039/501100011033 and Fondo Social Europeo Plus (FSE + ). AS-G and MPS-C were supported by contracts associated to PID2020-115218RB-I00 and PID2023-153284OB-100 grants. JP-U acknowledges a Juan de la Cierva fellowship from MCIN/AEI (FJC2021-046999-I). The cost of this publication has been paid in part by “ERDF A way of making Europe” funds.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuronal immunoproteasome and PFKFB3-forced glycolysis: key players in multiple sclerosis

  • Rodríguez-López, Claudia
  • Bolaños, Juan P.
  • Lucas, José Javier
In a recent study published in Cell, Woo et al. 1 investigated the role of the immunoproteasome and the metabolic regulator 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in neurons in the context of multiple sclerosis (MS)-related IFNγ signaling, finding new therapeutic targets for neurodegeneration in MS and possibly other related neuroinflammatory neurodegenerative disorders. The immunoproteasome is a variant of the constitutive proteasome, where the core catalytic subunits PSMB5 (β5), PSMB6 (β1), and PSMB7 (β2) are replaced by the inducible subunits PSMB8 (β5i), PSMB9 (β1i), and PSMB10 (β2i), which display slightly different hydrolytic profiles. The expression of the inducible subunits increases in most cell types in response to IFNγ, resulting in improved class I antigen processing. However, beyond this immune system function, the immunoproteasome has also been found to play specific regulatory roles, like redox signaling and oxidative stress, among others, in many cell types, including neurons, and the induction of the immunoproteasome in neurons has been implicated in different neurodegenerative diseases, as first reported for Huntington’s disease.2, This work was supported by Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/ 501100011033/FEDER, UE) grants PID2021-123141OB-I00 to J.J.L. and PID2022-138813OB-I00 to J.P.B., Peer reviewed